Revolution Med shoots for $100M+ IPO — and divulges some secrets about that Warp Drive buyout
Biotech investors who like to wager on the race to the front of the KRAS market now have a new team to consider.
Revolution Medicines, which extended its reach on RAS with a deal to acquire Warp Drive Bio about 18 months ago, filed their S-1 in search of $100 million-plus. And they gave up a few secrets in the process.
The main clinical claim to fame that Revolution has centered on is the SHP2 inhibitor RMC-4630, partnered with Sanofi back in the summer of 2018 — just after John Reed was named the incoming R&D chief. We already knew that the pharma giant handed over $50 million in cash plus a commitment of hundreds of millions more to align itself with Revolution as it makes a fresh foray into oncology. Now we know that Sanofi is also footing 80% of Revolution’s R&D bill on the program, while setting up a smorgasbord of $235 million in development milestones and $285 million in commercial bonuses.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.